SAGE - Sage Therapeutics GAAP EPS of -$2.12 beats by $0.05 revenue of $1.6M misses by $0.17M

Sage Therapeutics press release (NASDAQ:SAGE): Q4 GAAP EPS of -$2.12 beats by $0.05. Revenue of $1.6M (-99.9% Y/Y) misses by $0.17M. Ended 2021 with cash balance of $1.7 billion; anticipate ending 2022 with a cash balance of approximately $1.3 billion. The Company does not anticipate receipt of any milestone payments from collaborations in 2022. The Company believes its cash and cash equivalents, ongoing collaboration funding, and potential revenue, will support its operations into 2025.

For further details see:

Sage Therapeutics GAAP EPS of -$2.12 beats by $0.05, revenue of $1.6M misses by $0.17M